By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Daiichi Sankyo Company, Ltd. 

3-5-1, Nihonbashi-honcho

Chuo-ku  Tokyo  103-8426  Japan
Phone: +81-3-6225-1111 Fax:


Daiichi Sankyo is focused on the discovery and development of novel oncology agents with the goal of delivering first-in-class and best-in-class treatments that address unmet medical needs. The oncology pipeline of Daiichi Sankyo continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and hematological cancers.




CEO: Joji Nakayama


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Private

Web Site: Daiichi Sankyo


Company News
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress In Precision Medicine For Breast Cancer To Be Presented At 2017 ASCO Annual Meeting 5/24/2017 6:24:01 AM
Daiichi Sankyo Abandons 6 Clinical Programs in Q1 Update 5/11/2017 6:38:46 AM
Daiichi Sankyo Adds The Source-To-Pay Catalyst From Zycus To Boost Its Procurement Performance 5/11/2017 6:13:04 AM
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment To Support Acceleration Of Antibody Drug Conjugate Portfolio 4/27/2017 7:45:15 AM
Heptares Enters Agreement With Daiichi Sankyo To Discover And Develop Novel, Small-Molecules For The Treatment Of Pain 3/13/2017 6:47:57 AM
Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA (Edoxaban) In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention With Stenting 3/6/2017 6:28:23 AM
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017 6:21:54 AM
Daiichi Sankyo Shutters Yet Another R&D Facility 2/10/2017 6:22:46 AM
Charleston Laboratories And Daiichi Sankyo Receive Complete Response Letter From FDA For New Drug Application For CL-108 (Hydrocodone, Acetaminophen, Promethazine) Tablets For Oral Use 2/3/2017 11:23:16 AM
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017 8:42:50 AM